Compo Biomedical Technology
Date | Investors | Amount | Round |
---|---|---|---|
$14.0m | Series A | ||
CNY250m | Series B | ||
* | CNY100m Valuation: CNY1.3b | Series B | |
Total Funding | AUD96.0m |
Recent News about Compo Biomedical Technology
EditKangpu Biopharmaceuticals is a pioneering company in the biopharmaceutical sector, focusing on the development of first-in-class and best-in-class drug candidates. Utilizing proprietary technology platforms such as NeoMIDES, SelPDEiS, and X SYNERGY, Kangpu aims to address significant unmet medical needs. The company operates in the global healthcare market, primarily targeting chronic and difficult-to-treat conditions like Crohn's disease. Kangpu serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. The business model is centered around research and development, with revenue generated through the commercialization of its patented drug candidates and strategic partnerships. Kangpu's commitment to innovation and collaboration is evident in its robust pipeline and global patent portfolio. The company is led by Dr. Cheng, who brings extensive experience in market access strategy and value proposition optimization for pharmaceuticals and medical devices. Kangpu's vision is to transform and improve lives globally through novel therapeutics based on innovative scientific solutions. The company values its dedicated and ambitious team, offering attractive salary and benefits packages, including equity incentives, to attract top talent worldwide.
Keywords: biopharmaceuticals, drug development, proprietary technology, chronic diseases, innovation, global healthcare, market access, strategic partnerships, patented drugs, therapeutic efficacy.